Dostarlimab cancer cure. Dostarlimab previously was approved with carboplatin and paclitaxel, followed by single-agent dostarlimab, for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). Jun 11, 2025 · What is dostarlimab? Dostarlimab is used to treat adults with certain cancers after other treatments did not work or stopped working, and/or the cancer has returned, or it has spread or cannot be removed by surgery. Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). Dostarlimab-gxly injection is in a class of medications called monoclonal antibodies. . Feb 1, 2026 · Dostarlimab-gxly injection is used in combination with other cancer medicines (eg, carboplatin, paclitaxel), and then may be used alone to treat endometrial cancer (cancer of the lining of the uterus) in patients whose cancer has returned or it has spread. Dostarlimab previously was approved with carboplatin and paclitaxel, followed by single-agent dostarlimab, for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). This helps the person's immune system to fight against the cancer cells, and helps to slow tumor growth. It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. Aug 7, 2024 · Dostarlimab is an antibody used for the treatment of mismatch repair–deficient (dMMR), recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR Dec 12, 2022 · Dostarlimab Adult Medication This information from Lexicomp ® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Dostarlimab (JEMPERLI) is a PD-1 monoclonal antibody for the treatment of adult patients, with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer that has progressed on or following prior therapy with a platinum-containing regimen. Find out how you have it, possible side effects and other important information. It is a treatment for womb cancer that has spread or come back (advanced or recurrent womb cancer). Dostarlimab is a type of immunotherapy. It works by blocking the action of a certain protein in cancer cells. ef1dt, rkpy, 1q05z, cuyu, b2zya, bfwlt4, qu5cs, px9ly, caom2, vvru,